Hospital
Mercy Health - Defiance Hospital LLC
Mercy Health - Defiance Hospital LLC was paid $11.90M by Medicaid between Jan 2018 and Dec 2024, across 203 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 50% of everything it billed.
33Billing provider infoMERCY HEALTH - DEFIANCE HOSPITAL LLC
DEFIANCE, OH 43512
DEFIANCE, OH 43512
33aNPI1629011234assigned 06/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.90M
24GClaims233,972
24DCodes billed203
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#66 of 101
Median peer was paid$22.32M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,606 | $235K | |
| 2019 | 6,303 | $231K | |
| 2020 | 21,276 | $1.65M | |
| 2021 | 31,436 | $2.24M | |
| 2022 | 24,631 | $1.65M | |
| 2023 | 85,747 | $3.47M | |
| 2024incomplete | 57,973 | $2.43M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 50% | 65,052 | 52,614 | $6.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.4% | 5,779 | 5,209 | $640K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.2% | 5,312 | 4,318 | $624K |
| 95813 | 4.6% | 984 | 904 | $548K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.7% | 2,623 | 2,490 | $445K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 2,692 | 2,098 | $335K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.8% | 4,416 | 1,449 | $330K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.9% | 764 | 446 | $229K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 2,704 | 669 | $190K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 835 | 651 | $181K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 724 | 543 | $178K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 617 | 469 | $150K |
191 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 834 | $139K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,351 | $111K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 911 | $102K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 862 | $97K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 573 | $67K |
| 20610 | <1% | 447 | $66K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 348 | $66K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 524 | $59K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 536 | $55K |
| 80053 | Comprehensive metabolic panel | <1% | 6,932 | $51K |
| 90837 | Psychotherapy session, about an hour | <1% | 358 | $48K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 402 | $47K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 247 | $38K |
| 80061 | Lipid panel | <1% | 2,076 | $37K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 316 | $35K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 185 | $34K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,761 | $32K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,463 | $32K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,581 | $31K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 428 | $28K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,589 | $27K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,687 | $27K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,459 | $27K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,846 | $27K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,334 | $26K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 219 | $26K |
| 93886 | <1% | 121 | $23K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,076 | $22K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 223 | $22K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 204 | $22K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 270 | $21K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,755 | $20K |
| G0008 | Administration of influenza virus vaccine | <1% | 975 | $18K |
| 97161 | <1% | 289 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,256 | $17K |
| 87428 | <1% | 1,497 | $17K | |
| 84439 | <1% | 849 | $16K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 99 | $16K |
| 95912 | <1% | 69 | $16K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 327 | $16K |
| 95957 | <1% | 490 | $16K | |
| 95886 | <1% | 182 | $16K | |
| 11721 | <1% | 626 | $16K | |
| 82607 | <1% | 980 | $14K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,612 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,137 | $11K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,610 | $11K |
| 11720 | <1% | 412 | $11K | |
| 92250 | <1% | 199 | $10K | |
| 93880 | <1% | 178 | $10K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 83 | $9K |
| 84702 | <1% | 556 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,583 | $9K |
| 90686 | <1% | 726 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,189 | $9K |
| 73630 | <1% | 569 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 206 | $8K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 81 | $8K |
| 93017 | <1% | 90 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 19 | $8K |
| 73562 | <1% | 387 | $7K | |
| 90670 | <1% | 648 | $7K | |
| 82746 | <1% | 833 | $7K | |
| 72100 | <1% | 276 | $7K | |
| 85027 | <1% | 1,561 | $7K | |
| 81001 | <1% | 3,977 | $6K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 17 | $6K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 587 | $5K |
| 64483 | <1% | 16 | $5K | |
| 90648 | <1% | 653 | $5K | |
| 87480 | <1% | 629 | $5K | |
| 92083 | <1% | 63 | $4K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 476 | $4K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 45 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 327 | $4K |
| 82728 | <1% | 322 | $4K | |
| 82570 | <1% | 520 | $4K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 659 | $4K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,835 | $4K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 21 | $4K |
| 87660 | <1% | 626 | $4K | |
| 86803 | <1% | 186 | $4K | |
| 86780 | <1% | 318 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,535 | $3K |
| 97597 | <1% | 40 | $3K | |
| 83540 | <1% | 415 | $3K | |
| 95819 | <1% | 29 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 252 | $3K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 221 | $3K |
| 93976 | <1% | 25 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 130 | $3K |
| 74018 | <1% | 55 | $3K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 30 | $3K |
| 73610 | <1% | 140 | $3K | |
| 87510 | <1% | 626 | $3K | |
| 81003 | <1% | 1,301 | $3K | |
| 86140 | <1% | 198 | $3K | |
| 73030 | <1% | 153 | $3K | |
| 85652 | <1% | 423 | $3K | |
| 80326 | <1% | 411 | $3K | |
| 83550 | <1% | 378 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 76 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 29 | $2K |
| 86900 | <1% | 95 | $2K | |
| 82043 | <1% | 403 | $2K | |
| 83735 | <1% | 907 | $2K | |
| 90723 | <1% | 364 | $2K | |
| 84484 | <1% | 2,630 | $2K | |
| 90715 | <1% | 135 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,274 | $2K |
| 86225 | <1% | 103 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,344 | $2K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 43 | $2K |
| 85610 | <1% | 1,033 | $2K | |
| 71250 | <1% | 29 | $2K | |
| 87186 | <1% | 447 | $2K | |
| 80076 | <1% | 439 | $2K | |
| 73130 | <1% | 120 | $2K | |
| 86038 | <1% | 142 | $1K | |
| 90633 | <1% | 135 | $1K | |
| 90680 | <1% | 224 | $1K | |
| 86850 | <1% | 82 | $1K | |
| 83690 | <1% | 1,636 | $1K | |
| 81025 | <1% | 814 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 353 | $1K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 129 | $1K |
| 76801 | <1% | 32 | $988.67 | |
| 84703 | <1% | 701 | $952.34 | |
| 87807 | <1% | 191 | $910.24 | |
| 80347 | <1% | 117 | $901.24 | |
| 0011A | <1% | 84 | $856.80 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,620 | $750.42 |
| 82947 | <1% | 745 | $726.96 | |
| 85730 | <1% | 505 | $693.78 | |
| 86431 | <1% | 52 | $672.39 | |
| 87077 | <1% | 79 | $659.35 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 202 | $585.67 |
| 90656 | <1% | 70 | $571.93 | |
| 87340 | <1% | 65 | $535.93 | |
| 90710 | <1% | 96 | $493.35 | |
| 0012A | <1% | 63 | $474.00 | |
| 80355 | <1% | 118 | $452.13 | |
| 86901 | <1% | 94 | $410.31 | |
| 80320 | <1% | 53 | $400.02 | |
| 80364 | <1% | 116 | $392.89 | |
| 83037 | <1% | 26 | $336.68 | |
| 86147 | <1% | 49 | $333.22 | |
| 90674 | <1% | 16 | $298.76 | |
| 0031A | <1% | 15 | $288.80 | |
| 83880 | <1% | 228 | $249.28 | |
| 86762 | <1% | 19 | $243.32 | |
| 86787 | <1% | 18 | $218.82 | |
| 82565 | <1% | 19 | $210.37 | |
| 85379 | <1% | 502 | $187.68 | |
| 85651 | <1% | 55 | $185.85 | |
| 85018 | <1% | 23 | $131.78 | |
| 90661 | <1% | 20 | $129.82 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,212 | $129.67 |
| 83605 | <1% | 967 | $129.33 | |
| 87088 | <1% | 16 | $127.64 | |
| 87040 | <1% | 352 | $109.91 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 674 | $104.45 |
| 87205 | <1% | 19 | $103.91 | |
| 73110 | <1% | 27 | $84.05 | |
| 96376 | <1% | 184 | $67.31 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,404 | $62.55 |
| 82150 | <1% | 174 | $54.21 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 390 | $36.66 |
| 81002 | <1% | 14 | $36.28 | |
| 80143 | <1% | 31 | $34.87 | |
| 85613 | <1% | 26 | $23.36 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,023 | $19.26 |
| 80179 | <1% | 31 | $17.43 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,420 | $15.21 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 473 | $13.90 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,807 | $9.77 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 242 | $9.30 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 104 | $8.38 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 36 | $4.38 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 211 | $1.61 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 62 | $0.97 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 1,107 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 115 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 16 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 15 | $0.00 |
| 82248 | 0% | 20 | $0.00 | |
| 01936 | 0% | 44 | $0.00 | |
| 93892 | 0% | 56 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 22 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 17 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (VP REIMBURSEMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.